status ~ the access record, read from the FDA pages
Wolverine Legal Status, FDA 503A Category, and Compounding Access
Both of the blend's peptides sit in FDA's 503A Category 2 today — and both are on a scheduled FDA advisory-committee agenda for July 2026. Access is under active review; here is the present-tense picture, without guessing the outcome.
The Headline: Access Is Under Active FDA Review
The Wolverine legal status story has real momentum right now. Both of the blend's components — BPC-157 and TB-500 — are on the published agenda of an FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, listed as bulk drug substances being considered for inclusion on the 503A Bulks List [12]. That is the live, forward-looking fact: these peptides are actively being evaluated, and the framework that governs their compounding access could expand.
That is also exactly where the honesty has to hold. A PCAC discussion is a step in evaluation, not a final decision — inclusion on a final 503A bulks list is decided by FDA rulemaking informed by the committee, and being discussed is not being listed [13]. So the right way to read July 2026 is as a scheduled review of substances under evaluation, with the outcome genuinely unknown. Nothing has been reclassified, dated, or decided. What is true today is that access is being actively reconsidered.
The Present-Tense Fact: Both Components Are 503A Category 2
As of today, the FDA-citable status is the same for both peptides. FDA identified BPC-157 as a bulk drug substance that may present significant safety risks and placed it in Category 2 for 503A compounding, effective with the September 29, 2023 update to the nominated-substances list [11]. FDA separately identified "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — the exact fragment in this blend — as a bulk drug substance that may present significant safety risks and placed it in Category 2 with the same September 29, 2023 effective date [11].
What Category 2 means in practice: these are substances FDA has identified as raising significant safety risks, and they are not covered by the enforcement-discretion policy that applies to Category 1 [13]. FDA's stated concerns for these peptide entries include potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [11]. There is no component carve-out here: both BPC-157 and TB-500 are currently Category 2, so compounding-pharmacy access to the blend's ingredients is currently restricted, and neither peptide is an FDA-approved drug.
Both Peptides Are on the July 2026 Agenda — No Carve-Out
It is worth being precise about scope, because the blend has two ingredients and people sometimes assume only one is in play. Both are. FDA's public calendar for the July 23-24, 2026 PCAC meeting lists BPC-157 and TB-500 among the bulk drug substances being considered for inclusion on the 503A Bulks List [12]. The TB-500 entry corresponds to the thymosin beta-4 fragment (LKKTETQ) that defines this blend's second component.
There is no component carve-out and no split status: both peptides are currently Category 2, and both fall under this one scheduled review [12]. That single fact does two things at once — it confirms the access conversation is moving, and it confirms that, as of today, the matter is still open rather than resolved.
How Legally Compounded Peptide Access Works
Setting aside any single ingredient's eligibility, it helps to understand how a legally compounded medication is supposed to reach a patient in the first place. Under the Federal Food, Drug, and Cosmetic Act, drug compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient; Section 503B covers FDA-registered outsourcing facilities that compound larger batches under cGMP-style oversight [13].
The lawful pathway is sequential. A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate [13]. Telehealth here is simply one front-end channel for that prescriber consultation; it does not change which substances may be compounded and does not remove the need for a legitimate evaluation and a valid prescription [13]. If appropriate and lawful, the prescriber issues a valid, patient-specific prescription, which is then dispensed by a 503A compounding pharmacy or, for office and batch use, sourced from a 503B outsourcing facility.
The pathway carries one decisive caveat for this blend: a compounder may use a given active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules [13]. Ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands — and both of this blend's peptides are in that Category 2 position today [11]. This page is general information about the regulatory landscape, not medical or legal advice, and not an offer to supply any substance.